Abstract
Polycystic ovary syndrome (PCOS) is one of the most common endocrinopathies, which occurs in 4–21% of women during reproductive age and is the most common form of hyperandrogenism [1, 2]. The clinical manifestations of PCOS are diverse, and most of them accompany a woman throughout her life, varying depending on age, ethnicity, constitutional and other factors. Due to the increase in average life expectancy, modern women spend quite a long period in peri- and postmenopause, which determines the need to monitor the clinical manifestations of PCOS, its long-term complications, as well as the features of the onset and course of age-associated diseases in this endocrinopathy [3–6].
References
Carmina E., Rosato F., Jannì A., Rizzo M., Longo R.A. Extensive clinical experience: relative prevalence of different androgen excess disorders in 950 women referred because of clinical hyperandrogenism. J. Clin. Endocrino.l Metab. 2006; 91(1): 2–6. DOI: 10.1210/jc.2005-1457
Lizneva D., Suturina L., Walker W., Brakta S., Gavrilova-Jordan L., Azziz R. Criteria, prevalence, and phenotypes of polycystic ovary syndrome. Fertil. Steril. 2016; 106(1): 6–15. DOI: 10.1016/j. fertnstert.2016.05.003
Welt C.K., Carmina E. Clinical review: lifecycle of polycystic ovary syndrome (PCOS): from in utero to menopause. J. Clin. Endocrinol. Metab. 2013; 98(12): 4629–38. DOI: 10.1210/jc.2013-2375
Franks S., Berga S.L. Does PCOS have developmental origins? Fertil. Steril. 2012; 97(1): 2–6. DOI: 10.1016/j.fertnstert.2011.11.029
Brown Z.A., Louwers Y.V., Fong S.L., Valkenburg O., Birnie E., de Jong F.H. et al. The phenotype of polycystic ovary syndrome ameliorates with aging. Fertil. Steril. 2011; 96(5): 1259–65. DOI: 10.1016/j.fertnstert.2011.09.002
Baber R.J., Panay N., Fenton A.; IMS Writing Group. 2016 IMS Recommendations on women’s midlife health and menopause hormone therapy. Climacteric. 2016; 19(2): 109–50. DOI: 10.3109/13697137.2015.1129166
Zawadzki J., Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A., Givens J., Haseltine F., Haseltine G., eds. Polycystic ovary syndrome. Oxford: Blackwell Scientific; 1992: 377–84.
Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum. Reprod. 2004; 19(1): 41–7.
Azziz R., Carmina E., Dewailly D., Diamanti-Kandarakis E., EscobarMorreale H.F., Futterweit W. et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil. Steril. 2009; 91(2): 456–88. DOI: 10.1016/j. fertnstert.2008.06.035
This work is licensed under a Creative Commons Attribution 4.0 International License.